Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $1,015.00 target price on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on REGN. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an overweight rating in a research report on Friday, August 2nd. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an outperform rating and a $1,150.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an overweight rating in a research report on Friday, August 2nd. Canaccord Genuity Group reissued a buy rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Finally, Truist Financial reaffirmed a buy rating and set a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average price target of $1,109.70.

Regeneron Pharmaceuticals Stock Up 0.4 %

Regeneron Pharmaceuticals stock opened at $1,141.45 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm has a 50 day moving average price of $1,119.03 and a 200 day moving average price of $1,023.84. Regeneron Pharmaceuticals has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a market capitalization of $125.77 billion, a PE ratio of 33.72, a price-to-earnings-growth ratio of 3.86 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the company earned $8.79 earnings per share. The company’s revenue was up 12.3% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Michael S. Brown sold 1,535 shares of the company’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,437,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,535 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,437,280. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The disclosure for this sale can be found here. In the last three months, insiders sold 11,561 shares of company stock valued at $13,095,105. Corporate insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Sachetta LLC grew its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $26,000. West Paces Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the last quarter. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Finally, Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.